The impact of metabolic risk factors on gender differences in HCC development and treatment allocation
D. Smith,A. Cespiati,C. Bertelli,R. Lombardi,A.L. Fracanzani
DOI: https://doi.org/10.1016/j.dld.2024.01.159
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Introduction Liver's susceptibility to sexual hormones leads to gender differences in hepatocellular carcinoma (HCC). Metabolic comorbidities like obesity and diabetes, act as pro-oncogenic factors. Despite higher obesity rates in women, men with obesity face an increased HCC risk. The mechanism of this phenomenon is not fully understood. This study examines gender-based differences in HCC features and staging linked to metabolic comorbidities. Methods A retrospective evaluation was conducted, evaluating 126 patients (2014-2020) utilizing the Barcelona Clinic Liver Cancer (BCLC) system for staging and treatment decisions. A platelet count <150,000mm³ estimated portal hypertension in 65% of cases. Treatment distribution included 14% undergoing surgery, 74% receiving locoregional therapy, 3% systemic therapy, and 8% best supportive care. Results HCC prevalence was higher in men (78% vs. 22%), with men experiencing onset at a significantly younger age (67±11 vs. 74±11, p=0.04). Hepatitis C virus (HCV) was the primary etiology in both genders (41% in men vs. 70% in women, p=0.03). Men also presented with more lesions at onset (52% vs. 80%, p=0.03), were more diabetic (43% vs. 20%, p=0.04) and obese (64% vs. 38%, p=0.09). Metabolic comorbidities correlated with higher percentages of thrombocytopenia (71% vs. 56%, p=0.03) and hyperbilirubinemia (36% vs. 15%, p=0.04), regardless of gender. In multivariate analysis, the coexistence of metabolic risk factors strongly correlated with male gender (OR 10.8, p=0.04), low platelet levels (OR 6.7, p=0.03), and high bilirubin levels (OR 4.95, p=0.04), independently of age. However, multifocality at onset appeared to correlate with male gender (OR 10.5, p=0.04). Conclusion Our study establishes a robust association between metabolic risk factors and male gender, contributing to more severe liver disease and access to less curative treatments. Increased vigilance and early intervention for metabolic comorbidities are crucial for reducing disease progression risk and facilitating more curative HCC treatments.
gastroenterology & hepatology